{"id":"NCT03235349","sponsor":"AbbVie","briefTitle":"Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","officialTitle":"An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-29","primaryCompletion":"2018-11-15","completion":"2019-02-25","firstPosted":"2017-08-01","resultsPosted":"2019-11-21","lastUpdate":"2019-11-21"},"enrollment":160,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493/ABT-530","MAVYRET™"]}],"arms":[{"label":"Glecaprevir/Pibrentasvir","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon \\[pegIFN\\]) with or without ribavirin (RBV) OR sofosbuvir with RBV with or without IFN.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug, Week 24 or Week 28 depending on the treatment regimen.","effectByArm":[{"arm":"Glecaprevir/Pibrentasvir","deltaMin":99.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":5},"locations":{"siteCount":34,"countries":["China","South Korea"]},"refs":{"pmids":["32682494"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":160},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","URINARY TRACT INFECTION"]}}